TISIDB

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein
Domain	PF14575 Ephrin type-A receptor 2 transmembrane domain PF01404 Ephrin receptor ligand binding domain PF07699 Putative ephrin-receptor like PF00041 Fibronectin type III domain PF07714 Protein tyrosine kinase PF00536 SAM domain (Sterile alpha motif)
Function	Receptor tyrosine kinase which binds promiscuously GPI-anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Among GPI-anchored ephrin-A ligands, EFNA5 is a cognate/functional ligand for EPHA7 and their interaction regulates brain development modulating cell-cell adhesion and repulsion. Has a repellent activity on axons and is for instance involved in the guidance of corticothalamic axons and in the proper topographic mapping of retinal axons to the colliculus. May also regulate brain development through a caspase(CASP3)-dependent proapoptotic activity. Forward signaling may result in activation of components of the ERK signaling pathway including MAP2K1, MAP2K2, MAPK1 AND MAPK3 which are phosphorylated upon activation of EPHA7.

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0001655 urogenital system development GO:0001763 morphogenesis of a branching structure GO:0001822 kidney development GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007416 synapse assembly GO:0008361 regulation of cell size GO:0010721 negative regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010771 negative regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0010977 negative regulation of neuron projection development GO:0016049 cell growth GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0022407 regulation of cell-cell adhesion GO:0022604 regulation of cell morphogenesis GO:0030308 negative regulation of cell growth GO:0031290 retinal ganglion cell axon guidance GO:0031345 negative regulation of cell projection organization GO:0031952 regulation of protein autophosphorylation GO:0032535 regulation of cellular component size GO:0035239 tube morphogenesis GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043523 regulation of neuron apoptotic process GO:0043525 positive regulation of neuron apoptotic process GO:0045665 negative regulation of neuron differentiation GO:0045926 negative regulation of growth GO:0046777 protein autophosphorylation GO:0048013 ephrin receptor signaling pathway GO:0048588 developmental cell growth GO:0048638 regulation of developmental growth GO:0048640 negative regulation of developmental growth GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048668 collateral sprouting GO:0048670 regulation of collateral sprouting GO:0048671 negative regulation of collateral sprouting GO:0048755 branching morphogenesis of a nerve GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050768 negative regulation of neurogenesis GO:0050770 regulation of axonogenesis GO:0050771 negative regulation of axonogenesis GO:0050803 regulation of synapse structure or activity GO:0050807 regulation of synapse organization GO:0050808 synapse organization GO:0050919 negative chemotaxis GO:0051402 neuron apoptotic process GO:0051961 negative regulation of nervous system development GO:0051963 regulation of synapse assembly GO:0051964 negative regulation of synapse assembly GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0060560 developmental growth involved in morphogenesis GO:0060562 epithelial tube morphogenesis GO:0061387 regulation of extent of cell growth GO:0061564 axon development GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070997 neuron death GO:0072001 renal system development GO:0072073 kidney epithelium development GO:0072176 nephric duct development GO:0072178 nephric duct morphogenesis GO:0090066 regulation of anatomical structure size GO:0097485 neuron projection guidance GO:1901214 regulation of neuron death GO:1901216 positive regulation of neuron death GO:2000116 regulation of cysteine-type endopeptidase activity
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004714 transmembrane receptor protein tyrosine kinase activity GO:0005003 ephrin receptor activity GO:0005004 GPI-linked ephrin receptor activity GO:0008046 axon guidance receptor activity GO:0019199 transmembrane receptor protein kinase activity GO:0045499 chemorepellent activity GO:0046875 ephrin receptor binding
Cellular Component	GO:0030425 dendrite GO:0031594 neuromuscular junction GO:0043025 neuronal cell body GO:0044297 cell body GO:0045211 postsynaptic membrane GO:0097060 synaptic membrane GO:0098794 postsynapse

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04360 Axon guidance
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928665: EPH-ephrin mediated repulsion of cells R-HSA-3928663: EPHA-mediated growth cone collapse

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between EPHA7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of EPHA7 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of EPHA7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.033	0.881
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.09	0.875
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	0.999
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.745	0.322
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.018	0.55
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.395	0.84
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.338	0.651
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.054	0.447
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.44	0.771
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.667	0.621
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-1.163	0.532
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.108	0.728

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of EPHA7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	33.3	11	22.3	0.0146
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	33.3	13.6	19.7	0.0432
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	5.9	17.9	0.197
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	9.1	14	0.596
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	7.4	0.5	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	0	20	0.294

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPHA7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPHA7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPHA7. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPHA7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of EPHA7 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between EPHA7 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	EPHA7
Name	EPH receptor A7
Aliases	Hek11; EHK-3; EHK3; EK11; EPH homology kinase 3; EPH-like kinase 11; Eph homology kinase-3; receptor protein ......
Chromosomal Location	6q16.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting EPHA7 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting EPHA7.

ID	Name	Drug Type	Targets	#Targets
DB07970	5-[(2-methyl-5-{[3-(trifluoromethyl)phenyl]carbamoyl}phenyl)amino]pyridine-3-carboxamide	Small Molecule	EPHA7	1

Browse EPHA7